Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...

Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...

Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...

Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates...

Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today...

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...

MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...